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ABSTRACT
In combination with studies of post-mortem Parkinson’s disease (PD)
brains, pharmacological and genetic models of PD have suggested
that two fundamental interacting cellular processes are impaired –
proteostasis and mitochondrial respiration. We have re-examined the
role of mitochondrial dysfunction in lymphoblasts isolated from
individuals with idiopathic PD and an age-matched control group. As
previously reported for various PD cell types, the production of reactive
oxygen species (ROS) by PD lymphoblasts was significantly elevated.
However, this was not due to an impairment of mitochondrial
respiration, as is often assumed. Instead, basal mitochondrial
respiration and ATP synthesis are dramatically elevated in PD
lymphoblasts. The mitochondrial mass, genome copy number and
membrane potential were unaltered, but the expression of indicative
respiratory complex proteins was also elevated. This explains the
increased oxygen consumption rates by each of the respiratory
complexes in experimentally uncoupled mitochondria of iPD cells.
However, it was not attributable to increased activity of the stress- and
energy-sensing protein kinase AMPK, a regulator of mitochondrial
biogenesis and activity. The respiratory differences between iPD and
control cells were sufficiently dramatic as to provide a potentially
sensitive and reliable biomarker of the disease state, unaffected by
disease duration (time since diagnosis) or clinical severity.
Lymphoblasts from control and PD individuals thus occupy two
distinct, quasi-stable steady states; a ‘normal’ and a ‘hyperactive’
state characterized by two different metabolic rates. The apparent
stability of the ‘hyperactive’ state in patient-derived lymphoblasts in the
face of patient ageing, ongoing disease andmounting disease severity
suggests an early, permanent switch to an alternativemetabolic steady
state. With its associated, elevated ROS production, the ‘hyperactive’
statemight not cause pathology to cells that are rapidly turned over, but
brain cells might accumulate long-term damage leading ultimately to
neurodegeneration and the loss of mitochondrial function observed
post-mortem. Whether the ‘hyperactive’ state in lymphoblasts is a
biomarker specifically of PD or more generally of neurodegenerative
disease remains to be determined.
KEY WORDS: Parkinson’s disease, Lymphoblast, Lymphocyte,
Mitochondria, Respiration, AMPK, Complex I, ATP, OXPHOS, ROS,
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INTRODUCTION
Two major, interconnected pathways have been implicated as
producing cytopathology in idiopathic Parkinson’s disease (iPD).
The first pathway is related to protein misfolding and aggregation
either as the result of increased aggregate production or decreased
elimination (Schapira et al., 2009; Schapira, 2011). The second
pathway is related to mitochondrial dysfunction, especially of the
mitochondrial respiratory chain largely involving mitochondrial
complex I (Schapira and Gegg, 2011; Keane et al., 2011; Exner
et al., 2012; Perier and Vila, 2012). However, currently there is not a
clear understanding of the link between cellular toxicity,
mitochondrial changes and the disease process. Previous reports
on mitochondrial dysfunction and PD have resulted in a commonly
held view that reductions in mitochondrial respiratory function
contribute to PD cytopathology (Schapira and Gegg, 2011; Keane
et al., 2011; Exner et al., 2012; Perier and Vila, 2012). The evidence
can be summarized as follows:
(1) Mitochondrial defects directly or indirectly affecting complex
I, caused either by mutations affecting mitochondrial proteins
or by certain toxins [e.g. rotenone, 1-methyl-4-phenyl-1,2,3,6-
tetrahydroperidine (MPTP), paraquat], can cause PD in humans and
animal models. However, this does not prove that impaired
mitochondrial function plays a causative role in the majority of
PD cases, which are idiopathic.
(2) Post-mortem brains of individuals with PD exhibit reduced
mitochondrial complex I activity and reduced expression of many
genes encoding mitochondrial proteins. However, it is not clear
whether this reduced mitochondrial function in post-mortem PD
brains is a cause or a result of the disease process.
(3) Elevated production of reactive oxygen species (ROS;
presumably derived from leakage of electrons directly to
molecular oxygen at the point where they would normally pass
from Complex I or II via ubiquinone to Complex III) has been
consistently reported from various cell types in individuals with PD.
However, elevated ROS production can result either from impaired
mitochondrial electron transport or from increased rates of
otherwise normal mitochondrial respiration.
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individuals with idiopathic PD (iPD) have produced contradictory
and collectively inconclusive results (Bravi et al., 1992; Yoshino
et al., 1992; Barroso et al., 1993; Martín et al., 1996; Parker and
Swerdlow, 1998; Müftüoğlu et al., 2003; Shinde and Pasupathy,
2006; Esteves et al., 2010; Cronin-Furman et al., 2013; Ambrosi
et al., 2014). To pursue this issue, we studied multiple parameters of
mitochondrial function in lymphoblastoid cells (hereafter referred to
as lymphoblasts) derived from peripheral blood lymphocytes of
individuals with iPD and age-matched controls. Why did we choose
blood-derived cells when, by definition, the pathological process in
iPD involves neural tissue in the brain? Firstly, blood is a highly
accessible human tissue, unlike the brain. Accordingly, there is a
great need for blood biomarkers of PD disease and progression, yet
this has been little studied. Secondly, recent evidence shows clearly
that blood cells are also somehow embroiled in the pathology of
iPD. Thus, several studies have revealed genes whose expression is
altered in iPD blood cells (Scherzer et al., 2007; Molochnikov et al.,
2012; Karlsson et al., 2013; Soreq et al., 2013; Zhang et al., 2014),
some of them already known to exhibit altered expression levels in
post-mortem substantia nigra of individuals with iPD (Grünblatt
et al., 2004; Simunovic et al., 2009; Mandel et al., 2005). These
include ALDH1A1 (aldehyde dehydrogenase family H1 subfamily
A1, also known as retinal dehydrogenase 1), PSMC4 (26S protease
regulatory subunit 6B) and SKP1A (S-phase kinase-associated
protein 1A), all of which exhibited reduced transcript levels in PD,
and HSPA8 (heat shock 70 kDa protein 8, also known as heat shock
cognate 71 kDa protein) whose transcript levels are elevated in PD
(Molochnikov et al., 2012).
The implication is that the cytopathology of iPD extends to blood
cells and that the differences between iPD and control lymphoblasts
might not only shed light on the underlying disease processes but
also provide readily accessible biomarkers for disease and/or its
progression. We report here that immortalized lymphocytes from
individuals with iPD and healthy controls do indeed exhibit
remarkable metabolic differences in the form of a dramatic elevation
of mitochondrial respiratory activity in iPD cells. This is
accompanied by a concomitant increase in the production of ROS,
a cytotoxic byproduct of respiration.
RESULTS
ROS production is elevated in iPD lymphoblasts, but
mitochondrial membrane potential is unaltered and ATP
steady-state levels are increased
Previous work has shown that cells from various tissues exhibit
elevated ROS production in individuals with PD compared with
controls (Dias et al., 2013). We therefore measured ROS production
in lymphoblasts from individuals with iPD and controls and found,
as expected, that ROS production was significantly elevated in the
cells from individuals with iPD compared with those from an age-
matched control group (Fig. 1A). This elevation of ROS production
could be caused by a blockade of the normal electron flow from
complex I and II through complexes III and IV to molecular oxygen,
leading to increased diversion of electrons directly to molecular
oxygen. Indeed, it is typically interpreted in this way. If the elevated
ROS production in iPD lymphoblasts was caused by a blockade of
electron transport at or downstream of the transfer of electrons to
complex III and IV, it should be accompanied by a reduction in
mitochondrial membrane potential. When we measured this,
however, we found no significant reduction in mitochondrial
membrane potential in iPD lymphoblasts compared with controls
(Fig. 1B). Another possible explanation for elevated ROS
production is that it simply results from increased rates of electron
transport, accompanied by an associated increase in the rate of
leakage of electrons directly to molecular oxygen. If this is true then
the elevated ROS production in iPD cells should be accompanied by
increased mitochondrial ATP production, whereas the reverse
should be true if the production of ROS is caused by a partial
blockade of normal respiratory electron transport. Fig. 1C shows
that iPD lymphoblasts exhibited elevated steady-state levels of ATP
compared with control lymphoblasts, supporting the idea that in the
iPD cells ATP production is increased.
Mitochondrial respiratorycomplexesare functionally normal
but dramatically more active in iPD lymphoblasts
An alternative to the conclusion that ATP production is increased in
iPD cells is that mitochondrial ATP production rates were actually
lower in the iPD cells, but that ATP consumption rates were also
Fig. 1. Alterations to parameters of mitochondrial function in PD lymphoblasts. (A) Reactive O2 species levels are elevated in lymphoblasts from individuals
with PD. Intracellular ROS levels weremeasured in lymphoblasts from PD and control individuals using MAK142 (Deep Red) fluorescence. Except for one control
cell line (which was assayed only once), the mean normalized fluorescence from 105 cells was measured in duplicate in at least three independent experiments.
The ROS fluorescence in the PD lines (n=30) was significantly elevated compared with controls (n=9) (single-sided Welch test). (B) Mitochondrial membrane
potential is unaltered in iPD lymphoblasts. The relative mitochondrial membrane potential (Δψm) was measured in lymphoblasts from PD and control individuals
using the ratio of MitoTracker Red CMXRos (Δψm-dependent) to MitoTracker Green (mitochondrial mass-dependent) fluorescence. Each PD (n=30) and control
(n=9) cell line was assayed in duplicate in at least three independent experiments and means were calculated. The mitochondrial membrane potential was not
significantly different in the PD and control samples (two-sided Welch t-test). (C) Steady-state ATP levels are elevated in lymphoblasts from individuals with PD.
Steady-state ATP levels were assayed using a luciferase-based luminescence assay in lymphoblasts from PD and control individuals. Each PD (n=30) and
control (n=9) cell line was assayed in duplicate in at least three independent experiments andmeans were calculated. The steady-state ATP levels in the PD lines
were elevated significantly (single-sided Welch test). Error bars are standard errors of the mean (s.e.m.).
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reduced, such that steady-state ATP levels increased. To distinguish
these possibilities, we used respirometry with a Seahorse XFe24
Extracellular Flux Analyser (Fig. 2A,B) to determine if the flux of
electrons from complexes I or II via complexes III and IV to
molecular oxygen was elevated or reduced in iPD lymphoblasts
compared with controls. Oxygen consumption rates (OCR in pmol/
min) were measured before (basal OCR, Fig. 2C) and after
successive addition of oligomycin (ATP synthase inhibitor),
CCCP (carbonyl cyanide m-chlorophenyl hydrazone, an
uncoupling protonophore), rotenone (complex I inhibitor) and
antimycin A (complex III inhibitor). From the resulting data we
determined the oligomycin-sensitive OCR associated with
respiratory ATP synthesis (Fig. 2D), the maximum OCR in
uncoupled mitochondria (Fig. 2E) and the OCR attributable to
Fig. 2. The rate of O2 consumption by
mitochondrial respiration is elevated in
lymphoblasts from individuals with PD.
Oxygen consumption rates (OCR in pmol/min)
were measured using a Seahorse Extracellular
Flux Analyzer for 8×105 lymphoblasts from PD
and control individuals. In each experiment the
OCR was measured before (basal respiration)
and after successive addition of oligomycin (ATP
synthase inhibitor), CCCP (uncoupling
protonophore), rotenone (complex I inhibitor) and
antimycin A (complex III inhibitor), allowing
determination of each of the components of
respiration as shown in panel (A). In each
experiment, data was collected and averaged
from four separate wells for each individual cell
line. A typical example of an experiment with
standard errors reflecting the between-well
variance within the experiment is shown in
panel (B). Each PD (n=30) and control (n=9) cell
line was assayed in at least three independent
experiments and means were calculated. From
this data, we determined the OCR attributable to
(C) basal respiration, (D) ATP synthesis,
(E) uncoupled (maximum) respiration,
(F) complex I activity, (G) complex II activity,
(H) mitochondrial activities other than ATP
synthesis (‘proton leak’), (I) processes not driven
by electron transport (‘non-mitochondrial’) and
(J) the spare capacity (excess of uncoupled over
basal respiration). Significance probabilities are
shown for each of the respiratory parameters. All
were elevated significantly in PD lymphoblasts
compared with controls (P<0.05, single-sided
Welch t-test). Error bars are s.e.m. (K) Multiple
regression analysis of the relationship between
ROS production and the parameters of
respiration shown in panels C to J showed that
ROS levels were correlated with the rate of basal
respiration. The analysis incorporated dummy
variables to allow distinction between control and
PD lymphoblasts and successive removal of
least significant coefficients until only significant
coefficients remained. The only remaining
significant coefficient (apart from the intercept)
was that shown, relating ROS levels to basal
metabolic rate, so that both control and PD values
lay on the same regression line. The significance
of the final regression is shown (P<0.05, two-
sided t-test).
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complex I activity (Fig. 2F), complex II activity (Fig. 2G),
mitochondrial functions (e.g. protein import) that are not ATP-
driven (so-called ‘proton leak’, Fig. 2H), non-respiratory oxygen
consumption (e.g. by cellular and mitochondrial oxygenases and
oxidases, Fig. 2I), and the respiratory ‘spare-capacity’ (excess
capacity of the respiratory electron transport chain that is not being
used in basal respiration, Fig. 2J). The results showed that in iPD
lymphoblasts, mitochondrial respiration and ATP synthesis rates are
dramatically elevated. This suggests that ROS production is higher
in individuals with PD because mitochondrial electron transport
rates are elevated. To verify if this is so, we conducted a multiple
regression analysis relating ROS levels to all of the above respiratory
parameters. ROS levels were significantly correlated with basal
metabolic rate (P=0.0014) and none of the other variables had any
significant additional effect on ROS levels (Fig. 2K). Furthermore,
there was no difference in this regression relationship between
control and PD cells. This result shows that ROS levels are elevated
in PD lymphoblasts because of elevated respiration rates, not
because of an impairment or blockade of mitochondrial electron
transport in the electron transport chain.
To confirm that mitochondrial electron transport is more active,
but unimpaired, in PD lymphoblasts compared with controls,
we examined the regression between basal metabolic rate and its
electron transport-driven components – O2 consumption by ATP
synthesis and the ‘proton leak’. These tight regression relationships
were also identical for PD and control lymphoblasts (Fig. 3), as were
the relationships between the maximum OCR and its component
complex I and complex II activities in uncoupled mitochondria
(Fig. 3). If specific mitochondrial electron transport complexes had
been impaired in the PD lymphoblasts, these regression relationships
would have been altered compared with controls; e.g. if complex I
activity was impaired it would have made a proportionately smaller
contribution to the maximum OCR in PD cells and the slope of the
regression relationship would have been reduced. Overall, our data
provide compelling evidence that mitochondrial respiratory function
is not impaired in PD lymphoblasts.
Expression ofmitochondrial OXPHOS complexes is elevated
in iPD lymphoblasts, but AMPK activity and mitochondrial
mass are not
Considering the foregoing data, we hypothesized that rather than
a disease-causing impairment of mitochondrial respiration, PD
lymphoblasts exhibit an elevation of mitochondrial activity and
turnover that is elicited by a destructive cycle of cellular stress
signalling. Under this hypothesis, idiopathic PD cytopathology in
these cells would be initiated by a non-mitochondrial dysfunction
causing the activation of intracellular stress signalling pathways.
Once mitochondrial activities have been elevated in response to
stresses such as the accumulation of unfolded proteins, they would
in turn cause oxidative stress in the form of increased production of
reactive oxygen species. Various PD cell types are known to be
subjected to a variety of cellular stresses (Schapira et al., 2009;
Schapira, 2011; Dias et al., 2013; Placido et al., 2015). These
include oxidative stress and the accumulation of unfolded protein
aggregates such as the diagnostic α-synuclein-containing Lewy
bodies found in dopaminergic neurons in the substantia nigra. PD
leukocytes contain elevated levels of the oxidative DNA base
damage product 8-OH-2-deoxyguanosine (8-OHDG) (Chen et al.,
2009). Furthermore, the levels or activities of a variety of cellular
stress response proteins are altered in PD cells or experimental PD
models, including molecular chaperones (heat shock proteins) and
AMPK (Grünblatt et al., 2004; Simunovic et al., 2009; Mandel
et al., 2005; Liu and Chern, 2015; Santini et al., 2015). AMPK is a
stress-sensing protein kinase, best known for its activation by
energy stress such as occurs as a result of mitochondrial dysfunction
(Bokko et al., 2007), but also activated by a variety of other stresses
including the accumulation of unfolded protein aggregates,
hypoxia, elevated cytoplasmic Ca2+ levels and oxidative stress
(elevated ROS levels) (Hardie et al., 2012). If the lymphoblasts from
individuals with PD are chronically exposed to one or more of the
foregoing cellular stresses, then AMPK activity within them could
be elevated compared with control lymphoblasts. One of the
downstream consequences of elevated AMPK activity in cells is
known to be an increase in both the activity and biogenesis of
mitochondria (Hardie et al., 2012). This could explain why
mitochondrial function is so elevated in iPD lymphoblasts.
Conversely, the elevated steady-state ATP levels in iPD
lymphoblasts would be expected to inhibit AMPK activity. It was
therefore apposite to determine if steady-state AMPK activities are
elevated or suppressed in PD lymphoblasts. Fig. 4A shows that
AMPK activities are not significantly altered in lymphoblasts from
individuals with idiopathic PD. Thus, the dramatic elevation of
mitochondrial activity in these cells cannot be ascribed to a
constitutively high level of AMPK activity.
Although AMPK is a key upstream regulator of mitochondrial
biogenesis and proliferation, it is not the only one (Jornayvaz and
Shulman, 2010). It was therefore possible that the increased
mitochondrial respiratory activity of these cells were a result of
increased mitochondrial mass, even though AMPK activities were
Fig. 3. Regression relationships amongst the components of basal and
maximum (uncoupled) respiration. Multiple regression analysis was
conducted for each of the illustrated respiratory parameters against either the
basal respiration rate (top row) or the maximum (uncoupled) respiration rate
and dummy variables distinguishing PD and control groups (bottom row). Least
significant variables were removed successively until only significant
regression coefficients (P<0.05) remained in the model. All regressions were
highly significant, but there were no significant differences in the regressions
(slope or intercept) between PD and control groups. Plotted regression lines
were fitted by the least squares method. Each point represents the mean result
from at least three independent experiments on lymphoblasts from a single
participant. OCR=O2 consumption rate. Electron transport OCR is the sum of
the contributions of complex I and complex II to the maximum OCR.
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unchanged. To determine this, we measured mitochondrial mass and
mitochondrial gene copy number in iPD and control lymphoblasts.
Neither was significantly increased (Fig. 4B,C), consistent with the
unchanged AMPK activities in these cells. We conclude that the
increased mitochondrial respiration rates in iPD cells are due to
elevated activity of the mitochondria and not to increases in the
steady-state mitochondrial mass or genome copy number.
As the samemitochondrial mass in PD lymphoblasts is more active
in ATP generation compared with controls, we hypothesized that
mitochondrial proteins involved in oxidative phosphorylation
(OXPHOS) would be more highly expressed in PD cells compared
with controls. To test this, we measured the expression levels of two
indicative mitochondrial mRNAs encoded by mitochondrial genes
(Fig. 4D) and the levels of twoOXPHOSproteins encoded by nuclear
genes (Fig. 4E,F) and found all to be significantly greater in PD cells
compared with controls. Thus, the high rates of OXPHOS activity in
PD lymphoblasts seem to be accompanied by elevated expression of
OXPHOS proteins. Presumably the levels of TCA cycle enzymes
involved in substrate oxidation are also increased to match the
increased electron transport capacity of the mitochondria. This is
suggested by the elevated levels of the complex II subunit SDHB
(complex II is also a direct participant in the TCA cycle) and could
explain why only small or no changes are observed in studies of PD
mitochondria that measure respiratory complex activity normalized
against the activity of the TCA cycle enzyme, citrate synthase.
Mitochondrial respiratory activity in iPD lymphoblasts is
elevated regardless of patient age, disease duration or
disease severity
The increased production of ROS that is a byproduct of elevated
mitochondrial activity in iPD lymphoblasts could have several
undesirable consequences for the cells. One is that it activates the
cellular oxidative stress response and in a vicious feedback cycle then
further stimulates mitochondrial biogenesis, activity and turnover. A
second is that these reactive oxygen species, including hydrogen
peroxide, hydroxyl radicals, superoxide and singlet oxygen, non-
Fig. 4. Steady-state AMPK activity, mitochondrial mass and genome copy number are unchanged in PD lymphoblasts but oxphos mRNA and protein
expression are elevated. (A) AMPK activity is not altered in PD lymphoblasts. Each PD (n=30) and control (n=8) cell line was assayed in duplicate in each of at
least two independent experiments and means were calculated. AMPK activities in the PD cells were not elevated significantly (single-sided Welch t-test).
Quantitative western blots also revealed no significant change in the ratio of activated AMPK (phosphorylated α1 subunit) to total AMPK in PD cells (Fig. S1A).
(B) Mitochondrial mass is not elevated in PD lymphoblasts. Mitochondrial mass wasmeasured in lymphoblasts from PD and control individuals usingMitoTracker
Green fluorescence. Each PD (n=30) and control (n=9) cell line was assayed in at least three independent experiments and means were calculated. The
fluorescence in the PD lines was not significantly elevated (single-sided Welch test). (C) Mitochondrial genome copy number is unchanged in PD lymphoblasts.
Relativemitochondrial genome copy number wasmeasured in duplicate in semi-quantitative RT-PCR as the difference in qPCR threshold cycle number between
the mitochondrial genes encoding ND1 and ND4 (mitochondrially encoded subunits of complex I) and the nuclear gene encoding β2-microglobulin. Each PD
(n=30) and control (n=8) cell line was assayed in two or three independent experiments and means were calculated. The mitochondrial genome number was not
significantly different in the PD and control cell lines (single-sided Welch tests). Very similar results were obtained using the nuclear 18S rDNA genes as the
genome loading control (not shown). (D) Mitochondrial gene expression is elevated in PD lymphoblasts. Quantitative reverse transcription PCR was used to
assay ND1 and ND4mRNAs (mitochondrially encoded subunits of complex I) relative to the nuclear-encoded cytoplasmic 18S rRNA (which provided the internal
loading control). Each PD (n=26) and control (n=7) cell line was assayed in duplicate in one to five independent experiments and mean threshold cycle numbers
(Ct) were calculated. For all cell lines the differences between mRNA expression levels for both subunits and the corresponding averages for the control cell lines
were determined. These were found to be elevated significantly in the PD cells (single-sided Welch test). Similar results were found in a subset of samples using
the β2-microglobulin mRNA as the internal control (not shown). (E,F) Steady-state levels of OXPHOS proteins are elevated in PD lymphoblasts. (E) Crude
lymphoblast protein extracts were separated on SDS-PAGE and western blotted using commercial antibodies. The blot shown is an example with fluorescence
signals as shown for the ATP5A and SDHB bands, normalized to the corresponding α-tubulin signal in the same track and expressed relative to the average
control values. (F) Background-subtracted fluorescence signals for each band were normalized against the background-subtracted α-tubulin signal in the same
track and expressed relative to the average control value. The ATP5A and SDHB levels were significantly higher in PD cells (n=11 PD and n=6 controls, single-
sided Welch test). Similar results were found in experiments with 19 PD samples and four control samples using an anti-β-actin antibody to detect actin as the
internal loading control (Fig. S1B,C,D). Error bars are s.e.m.
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specifically damage key cellular macromolecules with which they
come into contact, including proteins, DNA and membrane lipids.
This could also contribute to a vicious feedback by eliciting greater
turnover of both mitochondria and other cellular components with
more ATP consumption and generation, consequential ROS
production and macromolecular damage. Elevated ROS production
in iPD cells is thus predicted to cause a gradual accumulation of
damage to mitochondrial respiratory complexes, the proteins in
closest proximity to the source of the ROS (Schapira, 2011; Schapira
and Gegg, 2011; Keane et al., 2011; Exner et al., 2012; Dias et al.,
2013). We therefore anticipated that as the disease progresses and
becomes more severe, the initially hyperelevated mitochondrial
respiratory function might decline. This could explain why
respiratory complex activities are reduced in post-mortem iPD
brains, even though they are not reproducibly lower in other types of
cells derived from live individuals and, as we have shown, are in fact
dramatically elevated in PD lymphoblasts.
To test if a decline in respiratory function during disease
progression is evident in PD lymphoblasts, we examined whether
there was a correlation between the various components of
mitochondrial respiration, the age of the patient and the duration
of clinical disease. We found that although the basal metabolic rate
and the OCR attributable to ATP synthesis declined slightly both
with patient age and with disease duration, neither of these effects
was statistically significant in a multiple regression analysis
(Fig. 5A,B; Fig. S2). Even in the oldest individuals with the
longest times since diagnosis, mitochondrial ATP synthesis rates
remained much higher than normal. When we examined if other
components of lymphoblast respiration changed as individuals aged
and disease progressed, we found that the only components of
mitochondrial respiratory function that changed significantly were
the maximum respiratory capacity and complex I activity after
treatment with the uncoupling protonophore CCCP. Both increased
with patient age but neither changed significantly with disease
progression (time) since diagnosis (Fig. 5C,D). None of the other
parameters of respiration in individuals with PD or control groups
changed significantly with age or disease duration (Fig. S2).
Likewise, the clinical measures of motor function and cognitive
decline (see Materials and Methods) were not significantly
correlated with any components of lymphoblast respiration
considered here (exemplified in Fig. S3 with UPDRS motor
scores, prorated IQ, basal respiration and ATP synthesis rates).
Although these negative results have been obtained in a small
number of subjects, we can infer that these relationships, even if
found significant in a larger sample, would not be strong. Thus, the
basal physiological state and metabolic need for ATP remained
elevated in PD lymphoblasts regardless of the course of the disease
and despite the high levels of ROS production.
Elevated mitochondrial respiratory activity could form the
basis of a blood test
It is widely recognized that a sensitive and specific biomarker of
Parkinson’s disease is needed to assist diagnosis and prognosis as
well as to test the efficacy of potential treatment regimes. Our results
have confirmed that blood cells are entangled in PD pathology and
have shown that several components of mitochondrial respiration in
lymphoblasts could provide such biomarkers. Receiver operating
characteristic (ROC) analysis of the use of the maximum uncoupled
O2 consumption rate of PD lymphoblasts suggested that it could
form the basis of a reliable test for PD (Fig. 6A,B; 100% specificity
Fig. 5. Regression relationships between
mitochondrial respiratory activity, patient age and
disease duration. The time since first diagnosis was
recorded as a surrogate measure of disease duration. For
plotting and analysis purposes, control participants were
deemed to have disease durations of 0. Planar surfaces
were fitted by least squares to show the relationships
between patient age and disease duration and (A) basal
OCR, (B) OCR attributable to mitochondrial ATP
synthesis, (C) maximum uncoupled OCR and (D)
maximum uncoupled OCR attributable to complex I.
In multiple linear regressions incorporating successive
removal of least significant coefficients and the use of
dummy variables to distinguish between PD and control
groups, the only significant regressions were those
relating the maximum OCR (P=8.09×10−4, two-sided
t-test) and complex I activity (P=2.09×10−3, two-sided
t-test) to PD patient age (Fig. S2). Basal OCR, ATP
synthesis, complex II activity, the proton leak and
non-respiratory OCR were not significantly affected by
patient age or disease duration (P>0.1, two-sided t-test).
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and 93.3% sensitivity, 99.3% reliability). Very similar and
statistically indistinguishable results (by DeLong’s test, Table S1)
(DeLong et al., 1988) were found using basal respiration rates
(Fig. 6C,D; P=0.48) and the respiratory activity of complex I
(Fig. 6E,F; P=0.48). These results reflect the dramatic nature of the
respiratory differences between lymphoblasts from the individuals
with PD and control groups and need to be confirmed in larger
studies. Furthermore, without wider studies encompassing other
diseases, we cannot tell whether these respiratory differences are
markers specifically of PD or more generally of neurodegeneration.
DISCUSSION
Our results have confirmed that iPD blood cells are different from
controls. In particular, the lymphocytes of individuals with iPD differ
from controls not only in their global gene expression patterns (Soreq
et al., 2013), but also in their metabolism when immortalized.
Although these results need to be confirmed in a much larger study,
they were dramatic – the rates of mitochondrial respiration, ATP
synthesis and maximum, uncoupled O2 consumption rates in
lymphoblasts from individuals with iPD were fourfold those of
control cells.
Despite these large increases, the steady-state ATP levels of PD
lymphoblasts were elevated only by about 75%, whereas the
respiratory spare capacity was elevated only by about 10% of
the basal OCR. These observations imply that the high rates of
electron transport and mitochondrial ATP synthesis in PD
lymphoblasts are matched by similarly increased rates of ATP
consumption. Part of this additional energy consumption can be
accounted for by increased rates of biogenesis of respiratory
enzymes. It has been reported previously that accumulation of
wild-type or a PD-causing mutant form of α-synuclein causes
increased autophagic turnover even of normal mitochondria in
neuronal cells (Choubey et al., 2011). This increased turnover of
mitochondria is energetically expensive and supporting it would
require the same steady-state mitochondrial mass to be more active
in oxidative phosphorylation, as we observed. Another contributor
to the elevated ATP consumption by PD lymphoblasts might well
be the accelerated rate of growth of these cells that was previously
reported (Esteras et al., 2015). It is of interest that whole-body
resting respiration rates by individuals with iPD has also been
known for many years to be elevated, but only in some individuals
could this be attributed to the abnormal neuromuscular state
(Levi et al., 1990).
The respiration, ATP synthesis and ROS production rates in iPD
lymphoblasts remained elevated and unchanged in the face of
patient ageing, ongoing disease and increased disease severity. The
maximum OCR and complex I activity in uncoupled mitochondria
increased modestly (as a percentage of the basal OCR) with patient
age, but were unaffected by disease progression (time since
diagnosis) and severity. How can these observations be reconciled
with reports of impaired complex I activity in post-mortem PD
brains? Unlike lymphoblasts and lymphocytes, brain neurons are
long-lived, post-mitotic cells. Their longevity provides an
opportunity for ROS-mediated damage to accumulate over time
that does not pertain to the same extent to blood cells or their
cultured derivatives. Even though PD leukocytes do exhibit elevated
levels of the oxidative DNA base damage product 8-OH-2-
deoxyguanosine (8-OHDG) (Chen et al., 2009), there is no
evidence that oxidative damage to PD immune cells is sufficient
to produce immunopathological outcomes. This stands in stark
contrast to the affected brain regions of individuals with PD. It
seems likely that the relatively rapid turnover of blood cells allows
them to avoid the long-term adverse consequences of hyperactive
mitochondria. PD lymphoblasts might thus represent cells from
individuals with PD in which respiratory activity is dramatically and
permanently elevated to an extent that is unaffected by disease
progression. The implications of this are far-reaching.
Fig. 6. ROCcurve analysis of theuseof respiration ratesof lymphoblasts as
diagnostic tests for PD. The optimum test threshold was a maximum OCR of
335.84 pmol/min (A,B), a basal OCR of 228.92 pmol/min (C,D) or a complex I
activity of 263.55 pmol/min (E,F). Lymphoblasts exceeding this threshold indicate
PD with the indicated specificities (proportion of control individuals correctly
excluded) and sensitivities (proportion of PD individuals correctly diagnosed).
Areas under the curve (ameasure of test reliability) were 0.9926 (95%confidence
interval: 0.975-1.0, DeLong’s test) for the maximum OCR, 0.985 (95%
confidence interval: 0.953-1.0, DeLong’s test) for the basal OCR and 0.989 (95%
confidence interval: 0.964-1.0, DeLong’s test) for complex I activity.
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First, the accumulated oxidative damage in the brains of
individuals with PD could be caused cell-autonomously by
initially hyperactive mitochondria in the neurons themselves, or
by hyperactive lymphocytes and glial cells involved in the local
inflammation that accompanies neurodegeneration in affected
areas of PD brains (Perry, 2012; Mosley et al., 2012). Derived
as they are from immune system cells, PD lymphoblasts
might better represent activated inflammatory cells in the brain
than other cell types. The permanent mitochondrial hyperactivity
of these cells might be a major cause of ongoing
neurodegeneration.
Second, it is clear that PD can sometimes originate from
mitochondrial damage and impaired function, either from
environmental toxins or from mutations that directly affect the
mitochondria (Schapira and Gegg, 2011; Keane et al., 2011; Exner
et al., 2012; Perier and Vila, 2012). Thus, although our patient
cohort provided no examples of impaired mitochondrial respiration,
forms of PD have been reported that do involve such loss of
respiratory function. It seems probable that respirometric assays of
lymphoblasts would allow a clear distinction to be made between
what might be called primary mitochondrial and non-mitochondrial
forms of PD. Such distinctions might be important for diagnosis,
prognosis and determination of treatment options in the future,
perhaps not only for PD but also for other neurodegenerative
diseases in which mitochondrial dysfunction has been implicated,
including Alzheimer’s, Huntington’s and motor neuron diseases.
Third, the respiratory competence of cultured lymphoblasts might
reflect the physiological and molecular state of PD lymphocytes
right from the onset of the disease, before clinical diagnosis, before
treatment and before ROS-mediated cytopathological damage has
begun. Gene expression patterns in PD lymphocytes differ from
controls from early in the disease process (Soreq et al., 2013). In our
patient cohort, the shortest time since diagnosis was about 2 years,
whereas one of our patients was untreated. Lymphoblasts from both
of these individuals exhibited full-blown elevation of respiratory
activity. Elevated lymphoblast respiratory activity might thus be
present in Parkinson’s disease (or more generally in
neurodegenerative disease) not only before any treatment has
begun but also prior to clinical diagnosis and cellular disease
pathology.
Finally, the apparently permanent nature of the dramatic
elevation in PD lymphoblast respiratory activity suggests that
lymphoblasts can occupy two distinct quasi-stable steady states, a
‘normal’ and a ‘hyperactive’ state characterized by two different
metabolic rates. Fig. 7 illustrates these two alternative metabolic
states in a 3D-ellipsoidal median plot. The PD and control
lymphoblasts occupy clearly separated volumes in a 3-D
respiratory parameter space. The addition of the other respiratory
and biochemical parameters would separate the PD and control
lymphoblasts even further in what might be considered as
multidimensional metabolic space. Our data show that
lymphoblasts from PD and control individuals are found in these
two states regardless of the progression of the disease. This being
so, the beginning of the disease process could be initiated by an
event that causes a switch from the normal to the hyperactive state.
This could be an environmental insult or the outcome of some
stochastic event, contingent upon the individual’s genetic profile.
Such bistable switches are characteristic of complex systems that
involve multiple autoactivating and autoinhibiting homeostatic
feedbacks. Perhaps the complex molecular pathways that have so far
been implicated in PD are capable of such bistable switching and
circumstances might exist that reverse the switch.
MATERIALS AND METHODS
Participant cohort
Datacollection and analysiswere conducted as part of a larger studyon the role
of the small CGG expansion FMR1 alleles in parkinsonism, supported by
NIH, and approved by the Human Ethics Committees of La Trobe University,
and of the RoyalMelbourneHospital inMelbourne, Australia. All participants
were asked and gave informed consent for their involvement in the study. All
individualswith PDand normal, healthy controlswerewhite,male Caucasians
aged from 28 to 85 and were of European (mainly northern European) origin,
residing inAustralia. Although the larger PD cohort included three individuals
that were younger than the youngest of the controls, the age distributions of the
two cohorts were not significantly different (Mann–Whitney U-test, P=0.96;
Fig. S5). All the participants were recruited from the Movement Disorders
clinic of the University ofMelbourne and theywere diagnosed by amovement
disorders specialist (AE) as having idiopathic Parkinson’s disease (iPD)
according to the Parkinson’s UK Brain Bank criteria (Hughes et al., 2002).
Two individuals, aged 28 and 30 years, had atypical iPD in which early-onset
parkinsonismwas associated with epilepsy and psychiatric problems andwere
included because their cell biological and biochemical alterations were not
different from those of the remaining iPD participants. One individual had
unclassifiable parkinsonism and is under ongoing review. All patients were
receiving treatment with levodopa and equivalents, with a daily dosage
(LEDD) of 9.3 varying between individuals towards achieving an optimal
effect. The treatment duration was, on average, one year less than disease
duration. None of the individuals showed any evidence of dementia. Control
participantswere recruited separatelyand did not have anyknownneurological
disorders or other conditions that might have been relevant to the study.
Neurological and neuropsychological assessments
Standard neurological assessment and ratings consisting of the Unified
Parkinson’s Disease Rating Scale Part III–Motor (UPDRS–III) (Fahn and
Elton, 1987) were conducted and scored by A.E. in subjects on their usual
PD medications. All cognitive tests were administered by a trained
neuropsychologist (E.H.). The Addenbrooke’s Cognitive Examination–
Revised (ACE–R) combines a number of subscales including attention and
orientation, memory, fluency, language and visuospatial (Mioshi et al.,
2006). The overall test score ranges from 0 to 100, with a cut-off score of
Fig. 7. PD and control lymphoblasts occupy distinct regions in
multidimensional metabolic space. The dramatic differences between PD
and control lymphoblasts in respiratory and associated biochemical
parameters can be visualized in the form of distinct regions of a
multidimensional metabolic space. The figure illustrates this by depicting the
median ellipsoidal surface fit to the results for three of the respiratory measures
(OCR in pmol/min) that separated the two groups most clearly – complex I
activity in the x axis, the maximum respiratory capacity in the y axis and the
basal metabolic rate in the z axis. The existence of these two different
metabolic states was confirmed in principal components analysis (Fig. S4),
which accounts for and removes the effect of cross-correlations between
variables.
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<88 giving 94% sensitivity and 89% specificity for dementia (Mioshi et al.,
2006). A number of subtests from theWechsler Adult Intelligence Scale 3rd
Edition (WAIS–III) included the Vocabulary subtest used to test basic word
knowledge; Similarities and Matrix Reasoning used to test the aspects of
executive functioning; and Digit Span used as the measures of working
memory (Wechsler, 1997). The Matrix Reasoning and Vocabulary subtests
were used to calculate a prorated IQ (Engelhart et al., 1999). The Symbol
Digit Modalities Test (Smith, 1973) was employed as the measure of
processing speed. This test was selected as it has an oral or verbal option,
which allowed for assessment of processing speed without a motor
component, which was important in this population.
Isolation and maintenance of lymphoblastoid cell lines
Lymphoblastoid cell lines were created by EBV-mediated transformation
of cells from the peripheral blood mononuclear cell (PBMC) layer at the
interface of Ficoll-paque Plus (Sigma-Aldrich) gradients. In each case, an
aliquot of 1×106 PBMCs was transformed with EBV from the cell line B95.8
using cyclosporin A (Sigma-Aldrich) to reduce the innate immune response
and rejection of the virus. Upon successful establishment, cell lines were
expanded into larger cultures and stored at −80°C in multiple aliquots of
5×106 cells in 500 µl Recovery Cell Culture Freezing Medium (Life
Technologies, 12648010) before proceeding to experimentation. For
experimental testing, aliquots were taken from storage and allowed to
defrost at room temperature. The cells were transferred into 10 ml of fresh
MEMAlpha medium supplemented with 10% foetal bovine serum (FBS)
(Gibco) and 1% pen/strep (Gibco), then grown and maintained at 37°C in a
humidified atmosphere with 5%CO2. All experiments were conducted within
10 passages of recovery from frozen storage. For the ROS assays, cell lines
were cultured in RPMI (Gibco) supplemented with 10% FBS, 1% pen/strep
and 1× Glutamax (Gibco) at 37°C in a humidified atmosphere of 5% CO2.
AMPK activity assay
AMPK immunoprecipitation, AMPK activity assays and western blot
analysis used lysates from confluent cell lines (∼25 ml) grown in T75 flasks,
harvested, lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 50 mM NaF, 5 mM sodium
pyrophosphate) supplemented with phosphatase inhibitors then snap-frozen
in liquid nitrogen. Thawed lysates were cleared by centrifugation at 10,000 g
for 5 min. Supernatant total protein concentrations were determined with the
Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific).
Antibody preparation and immunoprecipitation
Antibody preparation and immunoprecipitation were as described previously
(Oakhill et al., 2010); 60 µl of ‘AMPK slurry’was prepared from1 mg of total
protein lysate by immunoprecipitation using rabbit polyclonal anti-AMPKα1
antibody bound to equilibrated protein A-agarose beads. After overnight
incubation at 4°C, the beads were recovered and washed four times by
centrifugation before being resuspended in 60 µl wash buffer (50 mMHEPES
pH 7.4, 150 mM NaCl, 10% glycerol, 0.1% Tween-20). The resulting
‘AMPK slurry’ provided 2×20 µl aliquots for AMPK assay and 20 µl for
western blot analysis.
AMPK activity assay
AMPK activity was assayed over 10 min at 30°C by adding 20 µl of AMPK
slurry to 15 µl buffer containing 100 µM SAMS synthetic peptide (NH2-
HMRSAMSGLHLVKRR-COOH), 5 mM MgCl2, 50 mM HEPES pH 7.4,
0.1% Tween-20 and 1 mM DTT. Reactions were started by adding [γ-32P]-
ATP (final concentration 200 μM) and stopped by spotting 21 µl onto P81
ion-exchange chromatography paper (Whatman, GE Healthcare). Liquid
scintillation counting (Perkin Elmer) was used to measure the incorporation
of 32P into the SAMS peptide. Duplicates were averaged and normalized
against values from the same internal control cell line, C105, in each
independent experiment.
Western blot of α-pT172 and AMPKα1 levels
The levels of α-pT172 phosphorylation in lymphoblast samples were
detected by immunoblotting in the presence of a set of α-pT172-AMPK/
AMPK internal standards ranging from 10-80%. The α-pT172 signal
was detected using anti-α-pT172 antibody (1:1000; Cell Signaling
Technologies, 2535S), followed by incubation with secondary anti-rabbit
IR680 (1:5000; LI-COR Biosciences, 925-68071). Total AMPKα1
signal was detected using AMPKα1 antibodies as described previously
(Oakhill et al., 2010) fluorescently labelled with IR800. Immunoblots
were visualised on an Odyssey infrared imaging system (LI-COR
Biosciences).
Mitochondrial membrane potential and mitochondrial mass
Two mitochondrial dyes, MitoTracker Green FM and MitoTracker Red
CMXRos (Thermo Fisher Scientific), were used to estimate mitochondrial
mass and membrane potential (Pendergrass et al., 2004; Cottet-Rousselle
et al., 2011; Martins et al., 2015; Henzi and Schwaller, 2015; Barbato et al.,
2015). Fluorescence microscopy confirmed that both dyes stained the
mitochondria with very little background staining of the cytosol (data not
shown). Three aliquots of 1×106 harvested cells were suspended in 1 ml
Dulbecco’s phosphate buffered saline (PBS) (Sigma-Aldrich) for 1 h at 37°
C under 5% CO2, then transferred to: (1) fresh PBS, (2) fresh PBS
containing 200 nM MitoTracker Red CMXRos or (3) fresh PBS containing
200 nM MitoTracker Green FM. After incubation in the dark at 37°C and
5% CO2 for 1 h, each aliquot of cells was transferred to 2 ml fresh PBS for
fluorescence measurements using a Modulus Fluorometer (Turner
Biosystems, Sunnyvale, CA). The Green Module (excitation 525 nm,
emission 580-640 nm) was used for MitoTracker Red CMXRos and the
Blue Module (excitation 460 nm, emission 515-570 nm) for Mitotracker
Green. The unstained aliquot of cells in PBS was used in each case to
measure background fluorescence. The background-subtracted green
fluorescence measured mitochondrial mass and the ratio of the red and
green background-subtracted fluorescences measured the membrane
potential. Measurements were made in duplicate for each cell line,
averaged and normalized within every experiment to the values for the
same arbitrarily selected control cell line (C105).
Respirometry
The Seahorse XFe24 Extracellular Flux Analyzer (Seahorse Bioscience)
was used to measure the oxygen consumption rate (OCR), a measure of
mitochondrial respiration in real-time in live intact lymphoblastoid cells.
Prior to inoculating cells, a 24-well PS cell culture plate was pre-coated with
4.5 µl Matrigel growth factor-reduced (GFR) basement membrane matrix,
Phenol-Red free, LDEV-free, 10 ml (Corning, 356231), diluted 1:2 in XF
assay medium (unbuffered DMEM supplemented with 2.5 mM glucose and
1 mM sodium pyruvate) and then allowed to dry completely. One hour prior
to the assay 8×105 cells in XF assay medium were inoculated into the
Matrigel-coated wells. Each cell linewas inoculated into four replicatewells.
Several measures of mitochondrial respiration, including basal respiration,
ATP-linked respiration, proton leak respiration, maximum respiration rate
and spare respiratory capacity, were derived from oxygen consumption rates
before and after the sequential addition of pharmacological agents (1 µM
oligomycin, 1 µM CCCP, 1 µM rotenone, 5 µM antimycin A) to the
respiring cells. Between successive additions, the O2 consumption rate was
measured and averaged over three measurement cycles (time points), each
cycle consisting of a mix step of 3 min, a wait of 2 min and a measurement
time of 3 min.
ATP assay
Steady-state ATP levels were measured as per the manufacturer’s
instructions using the ATP Determination Kit (Molecular Probes) and
100 µl of clarified cell lysate from 5×105 cells, diluted with 900 µl 28 mM
tricine buffer (pH 8.25). Luciferase-mediated ATP-driven luminescences
were measured in duplicate aliquots in the Modulus Fluorometer with the
chemiluminescence module (Turner Biosystems). Average background-
subtracted luminescences were used to determine ATP concentrations from
a standard curve constructed using tenfold serial dilutions of the ATP
standard (100 nM-1 µM). In each experiment, mean ATP levels (nmol per
106 cells) were normalized against the values obtained for a control cell line
(C101) within the same experiment.
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Mitochondrial DNA copy number
Total DNA was extracted from ∼5×106 cells using DNAzol (Molecular
Research Center, Inc.) according to the manufacturer’s instructions. To
measure mitochondrial DNA (mtDNA) copy number, semi-quantitative real-
time PCR was employed using the iQ5 real-time PCR detection system and
the SensiFAST SYBR & Fluorescein One-Step Kit (Bioline) for amplicon
detection. A fragment of each of the mitochondrial ND1 and ND4 genes was
amplified using the primers ND1F (5′-cacccaagaacagggtttgt-3′) and ND1R
(5′-tggccatgggattgttgttaa-3′), and MTND4F (5′-caaccttttcctccgacccc-3′) and
MTND4R (5′-ctggataagtggcgttggct-3′). For internal loading controls,
fragments of the nuclear-encoded mitochondrial gene β2-microglobulin
and the 18SrRNA subunit were amplified, using the primers B2-MGF
(5′-cactaggaccttctctgagc-3′) and B2-MGR (5′-ctacagcttgggaattcctgc-3′)
for β2-microglobulin and 18SrRNAF (5′-tagagggacaagtggcgttc-3′) and
18SrRNAR (5′-cgctgagccatgcagtgt-3′) for 18S rRNA. The threshold cycle
numbers obtained for theND1 andND4 genes were subtracted from those for
the β2-microglobulin and 18S rRNA genes to give normalized measures for
the relative mitochondrial genome copy number.
Mitochondrial gene expression
RNAwas extracted from ∼5×106 cells using TRIsure (Bioline), treated with
RQ1 DNase (Promega) according to the manufacturer’s instructions. To
measure gene expression, semi-quantitative reverse transcription (RT)-PCR
was used with the SensiFAST SYBR & Fluorescein One-Step Kit.
Fragments of the mitochondrial ND1 and ND4 cDNA were amplified
using the primers ND1F and ND1R, and MTND4F and MTND4R,
respectively, whereas a fragment of the 18SrRNA subunit rRNA was
amplified as the internal loading control using the primers 18SrRNAF and
18SrRNAR. The threshold cycle numbers obtained for the ND1 and ND4
genes were subtracted from those for the 18S rRNA gene to give an estimate
of the relative level of mitochondrial gene expression. In a small subset of
experiments the primers B2-MGF and B2-MGR were also used to amplify
β2-microglobulin mRNA as an internal mRNA loading control and
produced similar outcomes.
Semi-quantitative western blotting of mitochondrial OXPHOS
protein levels
Cells were lysed in SDS loading buffer (0.125 M Tris hydrochloride, 10%
glycerol, 4% SDS, 4 M urea, 10% mercaptoethanol and 0.0001%
Bromophenol Blue) with a protease inhibitor cocktail (cOmplete EDTA-
free, Roche). A small aliquot of each briefly sonicated sample was analysed
for total protein concentration using a Qubit Protein Assay Kit and Qubit 2.0
Fluorometer (Thermo Fisher Scientific) according to the manufacturer’s
instructions.
The samples were then heated to 85°C for 5 min and 300 µg of total
protein was loaded into each well in 12% SDS polyacrylamide gels. After
electrophoresis, proteins were transferred onto PVDF membranes
(Amersham Hybond-P, GE Healthcare) using a Trans Blot Turbo Blotting
apparatus (Bio-Rad) for 30 min at 25 V, 1.0 A, blocked for 1 h with blocking
buffer (5% skim milk, TBS) and incubated overnight with primary
antibodies (Total OXPHOS human WB antibody cocktail, Abcam,
ab110411) diluted 1:250 in blocking buffer. This cocktail is directed
against five OXPHOS proteins, of which only SDHB (29 kD) and ATP5A
(54 kD) gave clear fluorescence signals using Alexa Fluor 488-labelled
secondary antibody. An anti-alpha-tubulin antibody (1:1000; Abcam,
ab52866) or an anti-β-actin antibody (1:3000; Santa Cruz
Biotechnologies, sc-47778) was used as an internal loading control in
combination with an Alexa Fluor 647-labelled secondary antibody. The
secondary antibodies (diluted 1:1000 in TBS) were A11008 (Alexa Fluor
488 goat anti-rabbit IgG) and A21235 (Alexa Fluor 647 goat anti-mouse
IgG) both from Thermo Fisher Scientific. Following incubation with
antibodies the membranes were washed three times with TBS buffer
containing 0.5%Tween 20, scannedwith a Typhoon FLA7000 and analysed
using the Image Quant TL 1D v 8.1 software (GEHealthcare Life Sciences).
Reactive oxygen species levels
Intracellular ROS were detected in live cells using the Fluorometric
Intracellular ROS kit (Sigma-Aldrich). Cells were harvested and
resuspended in Dulbecco’s phosphate buffered saline (Sigma) at 5×105
cells/ml. To 500 µl of cells in microcentrifuge tubes, 600 µl of Master
Reaction Mix was added from the Fluorometric Intracellular ROS kit
(Sigma-Aldrich) after which the cells were incubated in darkness under 5%
CO2 at 37°C for 1 h. The fluorescence (λex=520 nm/λem=605 nm) was
measured in a Modulus Fluorometer (Turner Biosystems) using the Green
Module. An arbitrarily selected control cell line (C105) was used in every
experiment as an internal, normalization control for between-experiment
variation. The fluorescence is proportional to the amount of ROS present. In
separate control experiments the fluorescence was shown to be quenched
dramatically by addition of 100 mM mannitol, a colourless ROS trap that
works by reacting with hydroxyl radicals (data not shown).
Statistical analysis
All statistical and graphical analysis was conducted using R (R Core Team,
2013) and the R packages RCommander (Fox, 2005) and REzy (Kanda,
2013). Unless otherwise specified, two-sample tests used the Welch t-test.
The significance of individual coefficients in multiple regression analysis
was tested using t-tests. ROC (receiver operating characteristic) analysis was
applied to determine the efficacy of respiratory parameters for diagnostic
purposes and was as described by Fawcett (2006) and Zou et al. (2007).
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Martıń, M. A., Molina, J. A., Jiménez-Jiménez, F. J., Benito-León, J., Ortı-́Pareja,
M., Campos, Y. and Arenas, J. (1996). Respiratory-chain enzyme activities in
isolated mitochondria of lymphocytes from untreated Parkinson’s disease
patients. Neurology 46, 1343.
Martins, W. K., Costa, E. T., Cruz, M. C., Stolf, B. S., Miotto, R., Cordeiro, R. M.
and Baptista, M. S. (2015). Parallel damage in mitochondrial and lysosomal
compartments promotes efficient cell death with autophagy: the case of the
pentacyclic triterpenoids. Sci. Rep. 5, 12425.
Mioshi, E., Dawson, K., Mitchell, J., Arnold, R. and Hodges, J. R. (2006). The
Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test
battery for dementia screening. Int. J. Geriatr. Psychiatr. 21, 1078-1085.
Molochnikov, L., Rabey, J. M., Dobronevsky, E., Bonucelli, U., Ceravolo, R.,
Frosini, D., Grünblatt, E., Riederer, P., Jacob, C., Aharon-Peretz, J. et al.
(2012). A molecular signature in blood identifies early Parkinson’s disease. Mol.
Neurodegener. 7, 26.
Mosley, R. L., Hutter-Saunders, J. A., Stone, D. K. andGendelman, H. E. (2012).
Inflammation and adaptive immunity in Parkinson’s Disease. Cold Spring Harb.
Perspect. Med. 2, a009381.
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